Tislelizumab Combined With XELOX as Neoadjuvant Therapy for G/GEJ Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 18, 2022

Primary Completion Date

July 18, 2024

Study Completion Date

July 18, 2026

Conditions
Locally Advanced Gastric Adenocarcinoma
Interventions
DRUG

Tislelizumab combined with Oxaliplatin and Capecitabine

"Drugs:~1. Tistelizumab 200mg, iv.gtt, D1, Q3W;~2. Chemotherapy (XELOX) : oxaliplatin (130 mg/m2), iv.gtt, D1, Q3W; Capecitabine (1000mg/m2), P.O.B.I.D., D1-D14, Q3W.~Neoadjuvant therapy:~1. Tislelizumab combined with XELOX, Q3W, for 2\~3 cycles;~2. D2 radical gastrectomy after neoadjuvant therapy.~Adjuvant therapy:~1. From 4 to 8 weeks after surgery, the treatment dose was the same as above;~2. Patients who achieved MPR and non-MPR on pathological evaluation were treated with tirelizumab +XELOX 3\~8 cycles;~3. Tumor evaluation performed every 3 cycles;~4. The maximum duration of adjuvant therapy was not more than 8 cycles."

Trial Locations (1)

710000

RECRUITING

Xijing Hospital of Digestive Diseases, Xi'an

All Listed Sponsors
lead

Xijing Hospital

OTHER